Loading the records…
Loading the records…
The Freedom to Heal Act of 2025 (HR6434) is an early-stage bill that would expand Right to Try access to Schedule I investigational psychedelic drugs by creating a new DEA registration for physicians. The bill is in committee referral stage with a companion in the Senate (S3346). A recent Executive Order (April 18, 2026) accelerating psychedelic therapies aligns with this bill's intent. Pure-play psychedelic companies — $CMPS, $GHRS, $ATAI, $MNMD — are the structural beneficiaries, though the bill authorizes no direct funding and faces a long legislative path.
The sector has already priced in significant bullish sentiment from the April 18 Executive Order, with $CMPS, $GHRS, and $ATAI all up 29-57% over the past 30 days. However, this specific bill has seen zero legislative momentum in 4+ months. The market is likely over-attributing legislative progress to current prices. If the bill fails to advance, sector retracement is possible. The Executive Order provides a more durable catalyst — it directly directs FDA and HHS to accelerate psychedelic therapy development, which benefits all pure-play developers regardless of this bill's fate. Investors should watch for committee hearings (Energy and Commerce, Judiciary) and cosponsor additions as the key legislative signals. Without fresh action, the bill is effectively dormant.
What happened: On December 4, 2025, Rep. Dean (D-PA) introduced HR6434 with 17 cosponsors (both Democratic and Republican). The bill was referred to two House committees (Energy and Commerce; Judiciary). An identical companion bill, S3346, was introduced in the Senate and referred to the Judiciary Committee. This is an early-stage legislative action — no committee votes, no markups, no floor action have occurred. The bill remains in its initial referral phase with no further action in 4+ months, indicating slow legislative velocity.
The money trail: HR6434 authorizes ZERO direct federal spending. It establishes a regulatory mechanism — a special DEA registration — that allows physicians to administer Schedule I investigational drugs under existing Right to Try law. This is a regulatory expansion, not a funding vehicle. No grants, tax credits, or procurement dollars are created. The financial impact on companies is entirely indirect: it creates a new commercial channel for investigational drugs (drug supply agreements under Right to Try) that could generate early revenue before FDA approval. The April 18, 2026 Executive Order on Accelerating Medical Treatments for Serious Mental Illness is a significant tailwind — it creates a more favorable regulatory environment and may accelerate the timeline for FDA engagement on these therapies.
Structural winners and losers: Pure-play psychedelic developers with Schedule I investigational drugs are the direct beneficiaries. $CMPS (psilocybin, TRD), $GHRS (5-MeO-DMT, TRD), $ATAI (multiple psychedelic compounds), and (LSD, GAD) all have active clinical-stage programs that qualify under the Right to Try framework. The mechanism is narrow — it only applies to eligible patients (life-threatening conditions, exhausted approved treatments) — so the total addressable patient population is limited. Companies without Schedule I drugs or without ongoing investigational programs see no benefit.
Real market data analysis: The provided market data (as of April 28, 2026) shows significant sector volatility. $CMPS is at $8.44 (52-week high $10.21), down 3.54% in 7 days but up 57.17% in 30 days. $GHRS is at $19.85 (52-week high $24.66), up 4.75% in 7 days and 50.95% in 30 days. $ATAI is at $4.33 (52-week high $6.75), down 8.07% in 7 days but up 29.25% in 30 days. These 30-day gains correlate strongly with the April 18 Executive Order rather than this December 2025 bill, which has seen no action. The sector pricing reflects optimism about the regulatory environment broadly, not legislative momentum for this specific bill.
Timeline: This bill requires: (a) committee hearings and markups in both House Energy & Commerce and Judiciary, (b) House floor vote, (c) identical Senate passage (S3346), (d) Presidential signature. With no action since referral, the probability of passage in the 119th Congress is low. The Executive Order provides a more immediate and actionable catalyst for the sector. The bill's primary value is as a signaling mechanism of congressional interest in expanded psychedelic access.
Matched on shared policy language across AI analyses, with ticker & timing weight
Freedom to Heal Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
Innovative Therapies Centers of Excellence Act of 2025
Mental Health Research Accelerator Act of 2025
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →